Related Experiment Video
Updated: Jan 28, 2026
04:48
Establishing a Severe Corneal Inflammation Model in Rats Based on Corneal Epithelium Curettage Combined with Corneal Sutures
Published on: November 22, 2024
837
Corneal ulceration associated with Nivolumab use
Jack S Parker1,2, Wyatt Feagin3, Christopher Wang4
1Parker Cornea, 1720 University Blvd Suite 503, Birmingham, AL, 35233, USA.
American Journal of Ophthalmology Case Reports
|March 1, 2019
Summary
Nivolumab, an immunotherapy drug, can cause severe corneal ulcers. This case report highlights that these ulcers may respond to steroid treatment, offering a potential therapeutic approach for patients.
Area of Science:
- Ophthalmology
- Oncology
- Immunology
Background:
- Nivolumab is an immune checkpoint inhibitor used to treat metastatic melanoma.
- Ocular side effects of Nivolumab are uncommon but can be severe.
Observation:
- An 80-year-old woman developed an intractable corneal ulcer in her left eye during Nivolumab therapy for metastatic melanoma.
- The corneal ulcer was refractory to multiple treatments, including surgical intervention.
Findings:
- Topical prednisolone acetate was administered and proved curative for the corneal ulcer.
- This suggests a steroid-responsive mechanism underlying Nivolumab-associated corneal ulceration.
Implications:
- Nivolumab-associated corneal ulcers may represent a distinct clinical entity.
- Ophthalmologists should consider topical corticosteroids in managing such cases.
- Early recognition and treatment can prevent vision loss in patients receiving Nivolumab.
Related Concept Videos
01:28Peptic Ulcer Disease II: Pathophysiology
2.0K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.0K
01:30Peptic Ulcer Disease I: Introduction
795
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
795
01:26Peptic Ulcer Disease IV: Management
477
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
477
01:29Drugs for Treatment of Ulcerative Colitis in IBD
499
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
499
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
962
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
962
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
1.2K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.2K